AA
LEGN icon

AlphaCentric Advisors’s Legend Biotech LEGN Stock Holding History

AlphaCentric Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$140K Buy
+3,000
New +$152K 0.04% 142
2021
Q2 		– Sell
-20,000
Closed -$580K – 230
2021
Q1 		$580K Buy
+20,000
New +$546K 0.2% 39

Other funds holding LEGN

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

AlphaCentric Advisors's LEGN Position: Q4 2021 in Review

AlphaCentric Advisors opened a new position in Legend Biotech (LEGN) in Q4 2021: 3,000 shares worth $140K. The stake represents 0.04% of the portfolio and ranks #142 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in LEGN as recently as Q1 2021.

AlphaCentric Advisors first reported a position in LEGN in Q1 2021 and has held it in 2 quarters since. The position peaked at $580K in Q1 2021. 139 funds tracked by Wall St. Rank hold LEGN as of Q4 2021.

  • AlphaCentric Advisors held 3,000 shares of Legend Biotech worth $140K as of Q4 2021.
  • Legend Biotech was a new AlphaCentric Advisors position in Q4 2021.
  • Legend Biotech made up 0.04% of AlphaCentric Advisors's portfolio in Q4 2021, its #142 holding.
  • AlphaCentric Advisors first reported a position in Legend Biotech in Q1 2021 and has held it in 2 quarters since.
  • AlphaCentric Advisors's Legend Biotech position peaked at $580K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.